Skip to Content

Notice

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Method of Making a Vaccine for Anthrax

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Department of the Army, DoD.

ACTION:

Notice.

SUMMARY:

In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application Serial No. 09/520,215 entitled “Method of Making a Vaccine for Anthrax,” filed March 7, 2000. The United States Government, as represented by the Secretary of the Army has rights in this invention.

ADDRESSES:

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

A method of making a vaccine from a protective antigen. The protective antigen is useful against Bacillus anthracis. The protective antigen is produced by an asporogenic organism, which overproduces the desired antigen. The asporogenic organism is a recombinant asporogenic B. anthracis. The recombinant asporogenic B. anthracis was derived from a Δ Sterne-1(pPA102) strain of bacteria and binds to dye when grown on Congo Red Agar.

Start Signature

Luz D. Ortiz,

Army Federal Register Liaison Officer.

End Signature End Supplemental Information

[FR Doc. 02-11072 Filed 5-2-02; 8:45 am]

BILLING CODE 3710-08-M